SCHEMBL4649218

SCHEMBL4649218

CC(C)N1CCC[C@H]1COc1cccc2cc(S(=O)(=O)c3ccccc3)cnc12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.46
HTR6 P50406 4/20 0.46
HTR1A P08908 1/20 0.46
DRD2 P14416 1/20 0.46
HTR7 P34969 1/20 0.46
HTR2B P41595 1/20 0.40
CHRM3 P20309 1/20 0.38
KRAS P01116 1/20 0.37
CHRNB4 P30926 2/20 0.36
CHRNA3 P32297 2/20 0.36
CHRNB1 P11230 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FFAR2 O15552 1/20 0.36
CNR1 P21554 3/20 0.35
METAP2 P50579 1/20 0.35
EDNRA P25101 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4649191 0.88 CHRNB4 (0.50) HTR2AHTR6HTR1ADRD2HTR7
SCHEMBL4650018 0.81 GPR119 (0.42) CHRM3CHRNB4CHRNA3CHRNB1CHRNB2
SCHEMBL4649259 0.81 HTR2A (0.48) HTR2AHTR6HTR1ADRD2HTR7
SCHEMBL4649227 0.76 HTR1A (0.49) HTR2AHTR6HTR1ADRD2HTR7
SCHEMBL4649900 0.76 HTR1A (0.49) HTR2AHTR6HTR1ADRD2HTR7
SCHEMBL4649244 0.75 HTR6 (0.53) HTR2AHTR6HTR1ADRD2HTR7
SCHEMBL4649408 0.74 HTR6 (0.48) HTR2AHTR6HTR1ADRD2HTR7
SCHEMBL4649915 0.74 HTR6 (0.52) HTR2AHTR6HTR1ADRD2HTR7
SCHEMBL4650585 0.74 HTR6 (0.52) HTR2AHTR6HTR1ADRD2HTR7
SCHEMBL4650645 0.73 HTR6 (0.54) HTR2AHTR6HTR1ADRD2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730112-B1 3-((HETERO)ARYLSULFONYL)-8'[ (AMINOALKYL)OXY]QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LTD (GB) 2008-09-03 EP claimed
US-20070191345-A1 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders GLAXO GROUP LIMITED (GB) 2007-08-16 US claimed
EP-1730112-A1 3-((HETERO)ARYLSULFONYL)-8'[ (AMINOALKYL)OXY]QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2006-12-13 EP claimed
WO-2005095346-A1 3-((HETERO)ARYLSULFONYL)-8-` (AMINOALKYL)OXY!QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2005-10-13 WO claimed
US-20070191345-A1 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders GLAXO GROUP LIMITED (GB) 2007-08-16 US disclosed
US-20070191345-A1 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders GLAXO GROUP LIMITED (GB) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191345-A1 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders HTR6, HTR3B, HTR2C HTR2A 4/4885HTR6 1/4885HTR1A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.